These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34054800)

  • 41. Identification of potential missed opportunities for human papillomavirus (HPV) vaccination in women referred to an academic colposcopy clinic for evaluation of abnormal cervical cytology.
    Dorton BJ; Vitonis AF; Feldman S
    Hum Vaccin Immunother; 2016 Jun; 12(6):1639-45. PubMed ID: 26839185
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
    Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
    J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
    J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Provider factors associated with disparities in human papillomavirus vaccination among low-income 9- to 17-year-old girls.
    Vadaparampil ST; Staras SA; Malo TL; Eddleton KZ; Christie J; Rodriguez M; Giuliano AR; Shenkman EA
    Cancer; 2013 Feb; 119(3):621-8. PubMed ID: 23341308
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Vaccine and Cervical Cancer Screen project 2 (VACCS 2): Linking cervical cancer screening to a two-dose HPV vaccination schedule in the South-West District of Tshwane, Gauteng, South Africa.
    Snyman LC; Dreyer G; Visser C; Botha MH; van der Merwe FH
    S Afr Med J; 2015 Mar; 105(3):191-4. PubMed ID: 26294825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Retrospective Cohort Study of Young Women Spontaneously Choosing to Be Vaccinated against HPV: Outcomes from Their First Cervical Cancer Screening Test.
    Del Mistro A; Battagello J; Weis L; Bressan V; Selle V; Ramigni M; Dal Zotto A; Maggiolo A; Gori S; Frayle H; Zappa M; Zorzi M; The Consensus Study Veneto Working Group
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33809436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
    ; Romanowski B; de Borba PC; Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; Aoki F; Ramjattan B; Shier RM; Somani R; Barbier S; Blatter MM; Chambers C; Ferris D; Gall SA; Guerra FA; Harper DM; Hedrick JA; Henry DC; Korn AP; Kroll R; Moscicki AB; Rosenfeld WD; Sullivan BJ; Thoming CS; Tyring SK; Wheeler CM; Dubin G; Schuind A; Zahaf T; Greenacre M; Sgriobhadair A
    Lancet; 2009 Dec; 374(9706):1975-85. PubMed ID: 19962185
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Associations between HPV vaccination among women and their 11-14-year-old children.
    Kornides M; Head KJ; Feemster K; Zimet GD; Panozzo CA
    Hum Vaccin Immunother; 2019; 15(7-8):1824-1830. PubMed ID: 31295048
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact.
    Gilca V; Salmerón-Castro J; Sauvageau C; Ogilvie G; Landry M; Naus M; Lazcano-Ponce E
    Vaccine; 2018 Aug; 36(32 Pt A):4800-4805. PubMed ID: 29887322
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The GARDASIL vaccine can prevent cervical carcinoma caused by human papilloma virus (HPV) (results from our participation and from the study carried out in Greece).
    Ansstasiou-Fotaki P; Deligeoroglou E; Kreatsas G
    Akush Ginekol (Sofiia); 2007; 46(3):17-20. PubMed ID: 18018777
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.
    Woestenberg PJ; Bogaards JA; King AJ; Leussink S; van der Sande MA; Hoebe CJ; van Benthem BH;
    Int J Cancer; 2019 Jun; 144(11):2718-2727. PubMed ID: 30426502
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
    Arbyn M; Dillner J
    J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Recommendations for the definition of a policy on vaccination against papillomavirus in Mexico. Strategic Advisory Group of Experts of the World Health Organization].
    Lazcano-Ponce E; Salmerón-Castro J; García-Carrancá A; Aranda-Flores C; Madrid-Marina V; Gómez-Altamirano CM; Martínez-Montañez OG
    Salud Publica Mex; 2009; 51(4):336-41. PubMed ID: 19668929
    [No Abstract]   [Full Text] [Related]  

  • 54. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
    Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
    Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human Papillomavirus Vaccination After COVID-19.
    Toh ZQ; Russell FM; Garland SM; Mulholland EK; Patton G; Licciardi PV
    JNCI Cancer Spectr; 2021 Apr; 5(2):pkab011. PubMed ID: 33748668
    [TBL] [Abstract][Full Text] [Related]  

  • 56. No Vacillation on HPV Vaccination.
    Sipp D; Frazer IH; Rasko JEJ
    Cell; 2018 Mar; 172(6):1163-1167. PubMed ID: 29522737
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effects of a brief educational intervention on human papillomavirus knowledge and intention to initiate HPV vaccination in 18-26 year old young adults.
    Kester LM; Shedd-Steele RB; Dotson-Roberts CA; Smith J; Zimet GD
    Gynecol Oncol; 2014 Mar; 132 Suppl 1():S9-12. PubMed ID: 24384459
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Facilitators and barriers of human papillomavirus vaccine uptake in young females 18-26 years old in Singapore: A qualitative study.
    Lim ASE; Lim RBT
    Vaccine; 2019 Sep; 37(41):6030-6038. PubMed ID: 31473002
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
    Poljak M
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human papillomavirus vaccination and the primary prevention of cancer: implications for survivors of childhood cancer.
    Klosky JL; Foster RH; Hodges J; Peasant C; Gamble H; McDermott MJ; Rao P
    Stud Health Technol Inform; 2012; 172():33-42. PubMed ID: 22910499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.